BRPI1008058A2 - terapia antibiótica para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa - Google Patents

terapia antibiótica para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa

Info

Publication number
BRPI1008058A2
BRPI1008058A2 BRPI1008058A BRPI1008058A BRPI1008058A2 BR PI1008058 A2 BRPI1008058 A2 BR PI1008058A2 BR PI1008058 A BRPI1008058 A BR PI1008058A BR PI1008058 A BRPI1008058 A BR PI1008058A BR PI1008058 A2 BRPI1008058 A2 BR PI1008058A2
Authority
BR
Brazil
Prior art keywords
likelihood
reduce
bowel syndrome
irritable bowel
antibiotic therapy
Prior art date
Application number
BRPI1008058A
Other languages
English (en)
Inventor
Christopher Chang
Mark Pimentel
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of BRPI1008058A2 publication Critical patent/BRPI1008058A2/pt
Publication of BRPI1008058A8 publication Critical patent/BRPI1008058A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008058A 2009-02-11 2010-02-11 uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa BRPI1008058A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15177209P 2009-02-11 2009-02-11
PCT/US2010/023873 WO2010093776A1 (en) 2009-02-11 2010-02-11 Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome

Publications (2)

Publication Number Publication Date
BRPI1008058A2 true BRPI1008058A2 (pt) 2016-03-15
BRPI1008058A8 BRPI1008058A8 (pt) 2018-03-27

Family

ID=42562059

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008058A BRPI1008058A8 (pt) 2009-02-11 2010-02-11 uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa

Country Status (8)

Country Link
US (1) US20110294726A1 (pt)
EP (1) EP2396029A4 (pt)
AU (1) AU2010213773B2 (pt)
BR (1) BRPI1008058A8 (pt)
CA (1) CA2752020A1 (pt)
CL (1) CL2011001943A1 (pt)
MX (1) MX2011008354A (pt)
WO (1) WO2010093776A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK2396652T3 (da) 2009-02-11 2018-01-29 Cedars Sinai Medical Center Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin
CA2778181C (en) 2009-10-26 2024-05-28 Thomas Julius Borody Therapy for enteric infections
CN103562240B (zh) * 2011-06-03 2017-02-15 巴斯夫欧洲公司 连续制备吸水性聚合物颗粒的方法
AU2013212008A1 (en) 2012-01-25 2014-07-10 Alfa Wassermann S.P.A. Rifaximin derivative and uses thereof
EP2895856B1 (en) 2012-09-17 2017-10-04 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
ES2691485T3 (es) * 2012-10-10 2018-11-27 Stc.Unm Métodos para el diagnóstico de infecciones bacterianas
BR112016007474A2 (pt) 2013-10-09 2017-09-12 Cedars Sinai Medical Center diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal
NZ730490A (en) 2014-10-09 2021-07-30 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
BR122024000249A2 (pt) * 2016-03-24 2024-02-27 Paratek Pharmaceuticals, Inc. Uso de um composto ou um sal do mesmo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0554291B2 (en) * 1990-10-22 2010-10-20 Centre For Digestive Diseases Pty Ltd Treatment of non-inflammatory bowel disorders
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
AU2003268330A1 (en) * 2002-08-29 2004-03-19 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
CN102634524B (zh) * 2003-12-05 2014-03-05 扶桑药品工业株式会社 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测
US20090233888A1 (en) * 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
DK2054066T3 (en) * 2006-08-02 2015-06-08 Salix Pharmaceuticals Inc METHODS OF TREATMENT OF RADIATE ENTERITIS
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
NZ587098A (en) * 2008-02-26 2012-09-28 Salix Pharmaceuticals Ltd Use of a rifamycin class antibiotic for treating diarrhea-associated Irritable Bowel Syndrome and hepatic encephalopathy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome

Also Published As

Publication number Publication date
US20110294726A1 (en) 2011-12-01
BRPI1008058A8 (pt) 2018-03-27
AU2010213773A1 (en) 2011-08-25
EP2396029A4 (en) 2012-08-08
CA2752020A1 (en) 2010-08-19
WO2010093776A1 (en) 2010-08-19
MX2011008354A (es) 2011-09-06
EP2396029A1 (en) 2011-12-21
AU2010213773B2 (en) 2014-07-17
CL2011001943A1 (es) 2012-02-03

Similar Documents

Publication Publication Date Title
BRPI1008058A2 (pt) terapia antibiótica para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa
ES2972892T3 (es) Tratamiento de la obesidad
DK3311828T3 (da) Modificerede vasoaktive tarmpeptider
DE112010002868A5 (de) Doppelkupplung
GB2479025B (en) Acoustic Reflectors
BR112012005371A2 (pt) desmontagem de componentes interligados
BRPI1012606A2 (pt) exposição multivalente de adjuvante
DK2339208T3 (da) Gear
DK2453858T3 (da) Fremgangsmåde
BRPI0923528A2 (pt) engrenagem intermediária
HK1166307A1 (en) Novel cyclopentane derivatives
DK2513115T3 (da) Tricycliske antibiotika
BR112012004643A2 (pt) compostos antibióticos
DE112010002723A5 (de) Doppelkupplung
GB0915315D0 (en) Use of non-digestible oligosaccharides
BRPI1013729A2 (pt) compostos bisazo
BR112012002575A2 (pt) utilização de uma composição.
BRPI1014266A2 (pt) Compostos bisazo
IT1393323B1 (it) Orologio da polso
BR112012013671A2 (pt) derivados halogenados de fty720
UA20620S (uk) Масажер
FI8673U1 (fi) Yhdistetyt soutumekanismit
GB0917714D0 (en) Acoustic reflectors
GB0913388D0 (en) Acoustic reflectors
TH111747B (th) ยางล้อสูบลม

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2467 DE 17/04/2018 POR TER SIDO INDEVIDA.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained